A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
for
Solid Tumor, Adult, Colorectal Cancer, NSCLC,
Location: New York NY, Jacksonville FL, Tampa FL, Columbus OH,
Sponsor: A2 Biotherapeutics Inc.
Sex: All
Age: 18+
Code: NCT06051695
Phase 1, Phase 2, Recruiting
Active & Responsive
Biomarkers to Detect Endocrine Therapy Resistance
for
Metastatic Cancer, Breast Cancer, Lobular Breast Carcinoma
Location: Madison WI
Sponsor: University of Wisconsin, Madison
Sex: All
Age: 18+
Code: NCT06067503
Phase 2, Recruiting
Active & Responsive
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
for
Localized Renal Pelvis and Ureter Urothelial Carcinoma,
Location: Seattle WA
Sponsor: University of Washington
Sex: Male
Age: 18+
Code: NCT01050504
Recruiting
Active & Responsive
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
for
Advanced Solid Tumors, Genital Neoplasm, Female,
Location: Boston MA, Bethesda MD, Toronto, Celebration FL,
Location: Boston MA, New Haven CT, Lake Success NY, New York NY,
Sponsor: Pheast Therapeutics
Sex: All
Age: 18+
Code: NCT06840886
Phase 1, Recruiting
Active & Responsive
Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
for
Pheochromocytoma, Paraganglioma, Inherited Cancer Syndrome,
Location: San Antonio TX
Sponsor: The University of Texas Health Science Center at San Antonio
Sex: All
Age: 0+
Code: NCT03160274
Recruiting
Active & Responsive
Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases
for
Clear Cell Renal Cell Cancer (ccRCC),
Location: San Francisco CA
Sponsor: Kelly Fitzgerald, MD
Sex: All
Age: 18+
Code: NCT07043608
Phase 2, Recruiting
Active & Responsive
Non-inferiority Study Comparing Salvage Pelvic Radiotherapy in 25 Fractions (62.5 Gy/25) Versus 20 Fractions (52.5 Gy/20) for Recurrent Prostate Cancer After Surgery.
for
Reccurent/Metastatic Solid Tumor Disease,
Location: Quebec
Sponsor: CHU de Quebec-Universite Laval
Sex: Male
Age: 18+
Code: NCT07483658
Recruiting
Active & Responsive
The EASE Study: Randomized Trial of a Novel Approach to Addressing Fear of Progression in Advanced Cancer
for
Advanced Solid Tumor Cancer,
Location: Aurora CO, Boulder CO
Sponsor: University of Colorado, Boulder
Sex: All
Age: 18+
Code: NCT07636200
Recruiting
Active & Responsive
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
for
Multiple Myeloma in Relapse, Myeloma Multiple,
Location: Boston MA, Hackensack NJ, Tampa FL, Atlanta GA,
Sponsor: Kelonia Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT07075185
Phase 1, Recruiting
Active & Responsive
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
for
AML (Acute Myeloid Leukemia), Glioma, Cholangiocarcinoma,
Location: New York NY, Orange CA
Sponsor: Rigel Pharmaceuticals
Sex: All
Age: 18+
Code: NCT07486713
Recruiting
Active & Responsive
Ambient Sensing Room to Detect Early Signs of Adverse Events in Hospitalized Patients With Cancer
for
Hematopoietic and Lymphatic System Neoplasm,
Location: Rochester MN
Sponsor: Mayo Clinic
Sex: All
Age: 18+
Code: NCT07477886
Recruiting
Active & Responsive
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
for
Advanced Solid Tumors, Metastatic Solid Tumors,
Location: Norwich CT, Fairfax VA, Nashville TN, Saint Paul MN,
Sponsor: Revolution Medicines, Inc.
Sex: All
Age: 18+
Code: NCT07397338
Phase 1, Phase 2, Recruiting
Active & Responsive
Evaluation of Early Identification of Cognitive Side Effects of Immunotherapy
for
Hematopoietic and Lymphatic System Neoplasm,
Location: Minneapolis MN
Sponsor: Masonic Cancer Center, University of Minnesota